Characteristics of the autonomous control of cardiac activity in patients with remitting multiple sclerosis
Belenko, E.A.; Vorob'eva, O.V.
Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 112(3 Part 1): 68-71
2012
ISSN/ISBN: 1997-7298 PMID: 22677760 Document Number: 657040
Document emailed within 1 workday
Related Documents
Losy, J.; Niezgoda, A.; Zaremba, J.ła. 2002: IL-15 is elevated in sera of patients with relapsing-remitting multiple sclerosis Folia Neuropathologica 40(3): 151-153Popova, E.V. 2008: Factors determining quality of life in patients with remitting multiple sclerosis Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 108(4): 77-80
Pokryszko-Dragan, A.; Bilińska, M.łg.; Gruszka, E.; Dubik-Jezierzańska, M. 2005: Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 19(113): 654-658
Pietropaolo, V.; Fioriti, D.; Mischitelli, M.; Anzivino, E.; Santini, M.; Millefiorini, E.; Di Rezze, S.; Degener, A.Marta. 2005: Detection of human herpesviruses and polyomaviruses DNA in a group of patients with relapsing-remitting multiple sclerosis New Microbiologica 28(3): 199-203
Cabrera-Gómez, J.A.; Echazábal-Santana, N.; Porrero-Martín, P.; Valenzuela-Silva, C.; Rodríguez, C.A.; Fuentes-Suárez, I.; Pérez-Ruiz, L.; Ramos-Cedeño, A.M.; Cabrera-Núñez, J.A. 2003: Interferon-alpha2b recombinant improved the cognitive dysfunction in patients with relapsing remitting multiple sclerosis Revista de Neurologia 37(3): 214-220
Stelmasiak, Z.; Bartosik-Psujek, H.; Belniak-Legieć, E.; Mitosek-Szewczyk, K. 2000: The effect of cladribine on some parameters of blood and cerebrospinal fluid in patients with relapsing-remitting multiple sclerosis (RR-MS) Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina 55: 221-225
Popova, E.V.; Brylev, L.V.; Davydovskaia, M.V. 2013: Natalizumab in the treatment of patients with relapsing-remitting multiple sclerosis: the preliminary results of the observational program "Sovet" Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 113(2 Pt 2): 79-82
Bilińska, M.łg.; Frydecka, I.; Kosmaczewska, A.; Ciszak, L.; Koszewicz, M.; Pokryszko-Dragan, A. 2006: CD40L expression on T CD4+ lymphocytes from peripheral blood in patients with relapsing-remitting and secondary progressive multiple sclerosis Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 20(115): 41-45
Le-Page, E.; Leray, E.; Taurin, G.; Coustans, M.; Chaperon, J.; Edan, G. 2006: Mitoxantrone as induction therapy in aggressive relapsing remitting multiple sclerosis: a descriptive analysis of 100 consecutive patients Revue Neurologique (Paris) 162(2): 185-194
Hennemann, A. 2002: Glatiramer for relapsing-remitting multiple sclerosis Medizinische Monatsschrift für Pharmazeuten 25(4): 141-142
Millar, J.A. 2019: The cost of teriflunomide in the treatment of relapsing-remitting multiple sclerosis New Zealand Medical Journal 132(1490): 36-41
Lebrun, C.; Ghetau, G.; Bourg, V.; Chanalet, S.; Chatel, M. 2005: Relapsing remitting multiple sclerosis or multiphasic disseminated encephalomyelitis? Revue Neurologique (Paris) 161(2): 228-233
Fernández-Fernández, O. 2002: Clinical features of relapsing remitting-multiple sclerosis. Prognostic factors Revista de Neurologia 35(11): 1067-1073
Bencsik, K.; Rajda, C.; Klivényi, P.; Járdánházy, T.; Török, M.; Vécsei, L. 1999: Treatment of relapsing-remitting multiple sclerosis with interferon beta type 1-b Orvosi Hetilap 140(14): 763-766
Pozdniakov, A.V.; Tiutin, L.A.; Bisaga, G.N.; Odinak, M.M. 2001: Proton magnetic-resonance spectroscopy in remitting and secondary-progressive multiple sclerosis Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 101(4): 36-39
Mugutdinova, B.T.; Boĭko, A.N.; Serkov, S.V.; Fadeeva, L.M.; Enikolopova, E.V.; Bogolepova, A.N.; Lashch, N.I.; Davydovskaia, M.F.; Khachanova, N.V.; Popova, N.F.; Shchur, S.G.; Riabukhina, O.V.; Romashkin, A.V.; Sidorenko, T.V.; Gusev, E.I. 2011: Data of MRi and neuropsychological tests predict the course of typical remitting multiple sclerosis during five years Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 111(2 Part 2): 29-37
Alcala-Vicente, C.; Perez-Miralles, F.C.; Gascon-Gimenez, F.; Bosca-Blasco, I.; Navarre-Gimeno, A.; Coret-Ferrer, F.; Casanova-Estruch, B. 2017: Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice Revista de Neurologia 64(10): 445-453
Rubio-Terrés, C.; Domínguez-Gil Hurlé, A. 2005: Cost-utility analysis of relapsing-remitting multiple sclerosis treatment with azathioprine or interferon beta in Spain Revista de Neurologia 40(12): 705-710
Baronica, K.B.ć; Mlinac, K.; Ozretić, D.; Vladić, A.; Bognar, S.K. 2011: Arylsulfatase a gene polymorphisms in relapsing remitting multiple sclerosis: genotype-phenotype correlation and estimation of disease progression Collegium Antropologicum 35(Suppl 1): 11-16
Schanke, A.K.; Grimsmo, J.; Sundet, K. 1995: Multiple sclerosis and prerequisites for driver's licence. A retrospective study of 33 patients with multiple sclerosis assessed at Sunnaas hospital Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 115(11): 1349-1352